Policy / Pricing SCOTUS backs generic firm Hikma in skinny label dispute PharmaphorumSCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.Read full story pharminent June 4, 2026 (Last updated: June 5, 2026) Pharmaphorum SCOTUS has delivered its ruling in a closely watched ‘skinny label’ lawsuit between Amarin and Hikma, which could have far-reaching implications. Read full story Post navigation Previous: ADC Therapeutics slumps on cancer drug safety scareNext: Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026